Valuation: Evotec

Market Cap 50Cr 58Cr 47Cr 43Cr 80Cr 5.53TCr 81Cr 563.18Cr 217.62Cr 2.8TCr 216.36Cr 211.55Cr 8.93TCr P/E 2026 *
-2.39x
P/E 2027 * -6.53x
Enterprise Value 64Cr 74Cr 61Cr 55Cr 103.24Cr 7.11TCr 103.86Cr 724.36Cr 279.9Cr 3.6TCr 278.28Cr 272.1Cr 11TCr EV / Sales 2026 *
1.07x
EV / Sales 2027 * 0.91x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO - 01/05/2026
Chief Operating Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 58 19/06/2019
Director/Board Member 64 01/06/2021
Director/Board Member 59 10/06/2024
Change 5-day change 1-year change 3-year change Capi.($)
-78.27%0.00% - - 58Cr
+0.26%+0.79%-1.21%+27.08% 4.59TCr
-0.32%+4.61%+43.90%+26.98% 4.42TCr
-4.36%-5.66%+338.30%+516.88% 4.2TCr
+0.46%-0.83%+6.38%+73.76% 3.96TCr
-0.17%-3.22%+10.29%+38.69% 3.11TCr
-0.65%+5.14%+25.61%+120.17% 1.72TCr
+3.30%-5.03% - - 1.63TCr
+2.09%+7.50%+21.44%+38.57% 1.5TCr
+0.86%+9.05%+0.47%-33.54% 1.34TCr
Average -7.70%+1.18%+55.65%+101.07% 2.94TCr
Weighted average by Cap. -0.51%+0.31%+70.18%+122.62%

Financials

2026 *2027 *
Net sales 60Cr 69Cr 57Cr 52Cr 97Cr 6.65TCr 97Cr 678.01Cr 261.99Cr 3.37TCr 260.47Cr 254.69Cr 11TCr 72Cr 84Cr 68Cr 62Cr 116.45Cr 8.02TCr 117.15Cr 817.04Cr 315.71Cr 4.07TCr 313.88Cr 306.91Cr 13TCr
Net income -20Cr -23Cr -19Cr -17Cr -32Cr -2.24TCr -33Cr -227.92Cr -88Cr -1.13TCr -88Cr -86Cr -3.62TCr -4.83Cr -5.57Cr -4.56Cr -4.14Cr -7.76Cr -534.13Cr -7.81Cr -54Cr -21Cr -270.91Cr -21Cr -20Cr -863.52Cr
Net Debt 14Cr 16Cr 14Cr 12Cr 23Cr 1.58TCr 23Cr 161.18Cr 62Cr 802.07Cr 62Cr 61Cr 2.56TCr 16Cr 19Cr 15Cr 14Cr 26Cr 1.8TCr 26Cr 182.98Cr 71Cr 910.53Cr 70Cr 69Cr 2.9TCr
Logo Evotec
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
2.808EUR
Average target price
4.586EUR
Spread / Average Target
+63.31%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!